/

ARCT

Arcturus Therapeutics Holdings Open

12.05−0.56 −4.44%USD

NasdaqGM · as of Oct 13, 12:39 ET · 15m delay

Open

12.42

Prev close

12.61

Day range

11.8612.65

52-week range

5.5024.17

Volume

183.89K0.20×

Mkt cap

342.50M

P/E ttm

—

Fwd P/E

-3.25

EPS ttm

-3.33

Div yield

0.00%

Earnings

Aug 6, 2026

From 52w high

−50.14%

Price Chart

Yahoo Finance · delayed

ARCTOct 13, 2026O 12.42H 12.65L 11.86C 12.05−0.56 (−4.44%)Vol 183.89K

SMA 5012.81
SMA 2008.73

1Y change −36.41% since Oct 10, 2025 close540 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

ARCT Arcturus Therapeutics Holdings · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −7.31%
1 month: −18.19%
3 months: +89.17%
6 months: +38.82%
Year to date: +96.57%
1 year: −37.85%

Valuation & ownership

Market cap: 342.50M
Enterprise value: 189.86M
P/E (ttm): —
Forward P/E: -3.25
PEG ratio: —
Price / book: 1.99
Price / sales (ttm): 11.66
EV / EBITDA: -1.91
EPS (ttm): -3.33
EPS (forward): -3.70
Beta (5y monthly): 2.48
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 28.42M
Float: 26.15M
Short % of float: 23.54%
Short ratio (days): 5.88
Held by insiders: 7.99%
Held by institutions: 77.37%
Avg volume (3m): 938.54K
50-day average: 12.68
200-day average: 8.70
52-week change: −37.85%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 42.4
vs 50-day SMA: −5.90%
vs 200-day SMA: +38.09%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 10.40%
Realised vol (20d, ann.): 98.4%
From 52-week high: −50.14%
From 52-week low: +119.09%

ANR

Analyst Consensus

10 analysts

Consensus

Strong buy

1.38 on a 1 (strong buy) – 5 (sell) scale

Mean target

23.80

+97.51% implied

Low 9.00Median 20.00High 41.00

Recommendation trend

Now11 / 2 / 0
1m ago / 2 /

DES

About Arcturus Therapeutics Holdings

Yahoo Finance profile

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Sector: Healthcare
Industry: Biotechnology
Employees: 106
Headquarters: San Diego, CA, United States
Website: arcturusrx.com
Officers: Mr. Joseph E. Payne M.Sc. Founder, President, CEO & Director
Dr. Padmanabh Chivukula Ph.D. Founder, Chief Scientific Officer, COO & Secretary
Mr. Joseph Roberts Principal Accounting Officer & Controller

SEAS

Seasonality · ARCT

2013–2026 · monthly returns

Strongest month Apr +11.08%Weakest month Oct −7.78%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	21.9	10.2	-6.2	11.7	-8.1	-15.2	-14.3	156.2	-7.2	-12.0			+96.6%
2025	0.0	-1.1	-36.9	21.0	-2.2	3.8	-6.1	39.3	8.3	-45.9	-31.9	-9.7	−63.9%
2024	4.6	17.6	-12.9	-24.3	51.8	-37.3	-3.7	-10.1	10.0	-23.6	3.4	-7.5	−46.2%
2023	24.6	-23.1	47.5	11.1	2.7	4.9	21.9	-13.2	-15.8	-25.2	25.3	31.7	+85.9%
2022	-29.4	-8.3	12.5	-28.1	2.6	-20.8	11.5	-20.0	5.6	19.4	4.2	-8.0	−54.2%
2021	67.0	-27.3	-21.6	-11.2	-20.3	15.8	-7.5	75.1	-12.8	-5.9	-11.6	-6.9	−14.7%
2020	-5.2	34.5	-1.9	153.9	12.9	20.0	11.7	-7.6	-11.1	26.1	69.7	-52.7	+299.1%
2019	10.4	0.8	35.5	11.1	-8.0	35.2	44.2	-17.5	-8.5	7.7	1.0	-2.7	+140.0%
2018	-2.4	-27.8	-1.8	-6.7	15.4	43.2	-5.9	1.5	9.1	-38.8	15.5	-27.5	−43.0%
2017	-50.0	24.8	-13.0	0.9	-3.5	0.9	-0.9	-7.2	-1.9	55.4	-19.7	-9.9	−45.9%
2016	-18.5	-9.0	-18.7	5.8	32.7	-15.6	-4.7	15.0	-49.8	-22.3	-0.5	9.9	−66.6%
2015	65.4	22.0	-25.2	4.4	31.0	-15.1	13.0	3.9	-21.4	37.9	-20.9	-4.7	+68.4%
2014	21.7	8.7	-23.8	-4.8	-1.0	1.2	0.6	10.6	-19.8	-76.6	2.2	0.8	−79.3%
2013						-4.9	51.1	24.5	40.0	-9.4	7.0	3.0	+150.0%

INSD

Insider Activity · ARCT

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 14, 2025	Sassine Andy HChief Financial Officer	Purchase at price 16.56 per share.	1.2K	$20.50K
Oct 14, 2024	Chivukula PadmanabhChief Operating Officer	Sale at price 20.76 per share.	12K	$249.12K

13F

Investors Holding ARCT

latest 13F filings of 29 followed managers

Investors holding ARCT
Investor	Value	Of portfolio	Shares	Change	Quarter
ARK Investment Management · Cathie Wood	$19.5M	0.13%	2.90M	+4.8%	Q2 2026
Renaissance Technologies	$143.8K	0.00%	21.40K	−88%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

ARCT

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

ARCT

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arcturus Therapeutics Holdings

Seasonality · ARCT

Insider Activity · ARCT

Congress Trades · ARCT

Investors Holding ARCT

Investors Holding ARCT

Congress Trades · ARCT

Insider Activity · ARCT

Seasonality · ARCT

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Arcturus Therapeutics Holdings

Financial Snapshot

Earnings & Dividends

News